Long-term follow-up of Korean CADASIL patients
Long-term Prognosis of Korean Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy(CADASIL) Patients: A Multicenter Prospective Study
This 10-year project will track symptoms, brain scans, cognitive tests, and genetic data in about 500 Korean adults with CADASIL to see how the disease progresses.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Jeju National University Hospital Academic / other |
| Locations | 1 site (Jeju City, Jeju-do) |
| Trial ID | NCT07497867 on ClinicalTrials.gov |
What this trial studies
K-CADASIL is a nationwide, multicenter prospective cohort that will enroll roughly 500 Korean adults with suspected or genetically confirmed CADASIL and follow them for 10 years. Participants will undergo regular clinic visits with neurological exams, MRI brain imaging, blood sampling, and standardized neuropsychological testing. Collected samples and data will form a genomic and proteomic biorepository to enable future multi-omics analyses. The program aims to link clinical features, imaging changes, comorbidities, and molecular markers to long-term outcomes in this population.
Who should consider this trial
Good fit: Adults (age 19 or older) in Korea with suspected or confirmed NOTCH3-related CADASIL who can provide informed consent are the intended participants.
Not a fit: People who cannot undergo MRI (for example due to pacemakers, metal implants, or severe claustrophobia) or who had an acute stroke within the last 180 days are likely to be excluded and may not benefit from participation.
Why it matters
Potential benefit: If successful, this work could improve predictions of disease course and help tailor monitoring and care for Korean patients with CADASIL.
How similar studies have performed: Large cohorts in Europe have described CADASIL natural history and genotype-phenotype links, but a long-term, multicenter Korean cohort of this size is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 19 years * CADASIL suspected or confirmed by genetic testing (NOTCH3 mutation) * Able to provide written informed consent (participant or legally authorized representative) Exclusion Criteria: * Contraindication to MRI (claustrophobia, metal implants, pacemaker) * Acute ischemic or hemorrhagic stroke within 180 days prior to enrollment
Where this trial is running
Jeju City, Jeju-do
- Jeju National University Hospital — Jeju City, Jeju-do, South Korea (Recruiting)
Study contacts
- Study coordinator: Jay Chol Professor Choi, MD, PhD, MD, PhD
- Email: jaychoi@jejunu.ac.kr
- Phone: +82-64-754-8160
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.